Genmab — Juli 2014
-
Ja måske. I den foreløbige godkendelse er det jo noget, der omtales. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002799/WC500167332.pdf
-
Jeg tror det handler om at EMA ikke vil acceptere et så latterligt navn som Gazyvaro og har bedt roche finde på noget nyt før de kan give en godkendelse
-
Og så tygger de jo stadig på denne http://www.reuters.com/article/2014/04/14/us-roche-hldg-europe-idUSBREA3D15A20140414
-
nedenstående kan bli´ guld værd for Genmab.. man skal huske på at det kender de enkelte læger kender jo også til problematikken og nu er der sået tvivl om evt. bivirkninger på ROCHE produkter
i almindelighed : "EMA launched its probe into Roche in 2012 after a routine inspection found the firm had failed to properly assess tens of thousands of cases of possible adverse drug reactions, involving 19 drugs, several of which were for cancer.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
